View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsNVN Liquidation 将来の成長Future 基準チェック /06現在、 NVN Liquidationの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Jul 05Price target decreased by 12% to US$11.50Down from US$13.00, the current price target is an average from 2 analysts. New target price is 2,296% above last closing price of US$0.48. Stock is down 80% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$1.42 last year.Major Estimate Revision • Jun 02Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$24.0m to US$21.2m. EPS estimate increased from -US$0.994 to -US$0.898 per share. Pharmaceuticals industry in the US expected to see average net income decline 24% next year. Consensus price target down from US$13.00 to US$11.50. Share price was steady at US$1.12 over the past week.Price Target Changed • Jun 02Price target decreased by 14% to US$11.50Down from US$13.40, the current price target is an average from 4 analysts. New target price is 927% above last closing price of US$1.12. Stock is down 59% over the past year. The company is forecast to post a net loss per share of US$0.90 next year compared to a net loss per share of US$1.42 last year.Major Estimate Revision • May 22Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$26.1m to US$24.0m. Losses expected to increase from US$0.86 per share to US$0.99. Pharmaceuticals industry in the US expected to see average net income decline 17% next year. Consensus price target down from US$13.40 to US$13.00. Share price rose 3.4% to US$1.20 over the past week.Price Target Changed • Mar 30Price target decreased by 13% to US$12.67Down from US$14.50, the current price target is an average from 6 analysts. New target price is 956% above last closing price of US$1.20. Stock is down 70% over the past year.Breakeven Date Change • Feb 24Forecast to breakeven in 2025The 6 analysts covering Novan expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$12.4m in 2025. Average annual earnings growth of 60% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Sep 29Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a stalking horse asset purchase agreement to acquire Substantially All of the Assets of Novan, Inc. for $30 million on July 17, 2023. Novan entered into a “stalking horse” asset purchase agreement with Ligand Pharmaceuticals to sell substantially all of the assets of the Company and its subsidiaries, including EPI Health (the “Purchased Assets”) for an upfront payment of $15 million. The cash payable at closing will be reduced dollar-for-dollar by the outstanding balance of the DIP Credit Facility which will be repaid at closing. The Purchase Agreement provides that the Company will pay a break-up fee to Ligand equal to $450,000 upon termination of the transaction in certain circumstances, including the entry into or consummation of an alternative transaction for the Purchased Assets with a party other than Ligand. Ligand Pharmaceuticals provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded. The transaction is part of a sale process under Section 363 of the Bankruptcy Code that will be subject to approval by the Bankruptcy Court and compliance with agreed upon and Bankruptcy Court-approved bidding procedures allowing for the submission of higher or otherwise better offers, and other agreed-upon conditions. The transaction is expected to close in the third quarter of 2023. Gerald F. Roach; Christopher B. Capel; James R. Jolley of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and Derek Abbot of Morris, Nichols, Arsht & Tunnell LLP acted as legal advisors for Novan. Craig Wolfe of Morgan, Lewis & Bockius LLP acted as legal advisor for Ligand Pharmaceuticals. Birch Lake is acting as financial advisor for Ligand Pharmaceuticals. Novan engaged Raymond James & Associates, Inc. andSIERRACONSTELLATION PARTNERS LLC. as financial advisor. Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc. on September 27, 2023.お知らせ • Sep 08Nasdaq To Delist the Common Stock of NovanNasdaq announced that it will delist the common stock of Novan, Inc. Novan, Inc.’s securities were suspended on July 26, 2023, and have not traded on Nasdaq since that time.お知らせ • Jul 27Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite IndexNovan, Inc. has been dropped from Nasdaq Composite Index.お知らせ • Jul 18+ 3 more updatesNovan's Securities to Be Delisted from NasdaqAs previously disclosed on July 17, 2023, Novan, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The case will be administered under the caption In re: Novan, Inc. et al, Case No. 23-10937. On July 17, 2023, the Company received written notice (the “Delisting Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the staff of Nasdaq has determined that the Company’s securities will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 filing and associated public interest concerns raised by it, concerns regarding the residual equity interest of the existing listed securities holders, and concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. The Company does not intend to appeal the delisting determination. Trading of the Company’s common stock will be suspended at the opening of business on July 26, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the common stock from listing and registration on Nasdaq. As a result, the Company’s common stock is expected to begin trading on the over-the-counter (“OTC”) market on July 26, 2023. On the OTC market, shares of the Company’s common stock, which previously traded on Nasdaq under the symbol NOVN, are expected to trade under the symbol NOVNQ.お知らせ • Jul 07Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS RequirementOn June 30, 2023, Novan, Inc. (the Company") received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq") notifying the Company that it is not in compliance with Listing Rule 5550(b)(2), which requires the Company to maintain a minimum market value of listed securities of at least $35 million (the MVLS Requirement") for continued listing on the Nasdaq Capital Market. The letter noted that, as of that date, the Company's market value of listed securities was below $35 million for at least 30 consecutive business days. In accordance with Nasdaq rules, the Company has been provided 180 calendar days, or until December 27, 2023, to regain compliance with the MVLS Requirement or else be subject to delisting. To regain compliance with the MVLS Requirement, the Company's market value of listed securities must close at $35 million or more for a minimum of ten consecutive business days during the 180 calendar-day compliance period. The notification received has no immediate effect on the Company's continued listing on the Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements. The Company continues to manage cash expenditures and cash flows, while pursuing various potential financing and strategic options to, among other things, advance its product candidate for molluscum contagiosum.Price Target Changed • Jul 05Price target decreased by 12% to US$11.50Down from US$13.00, the current price target is an average from 2 analysts. New target price is 2,296% above last closing price of US$0.48. Stock is down 80% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$1.42 last year.分析記事 • Jun 07Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)Novan, Inc.'s ( NASDAQ:NOVN ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a buy right now compared...Major Estimate Revision • Jun 02Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$24.0m to US$21.2m. EPS estimate increased from -US$0.994 to -US$0.898 per share. Pharmaceuticals industry in the US expected to see average net income decline 24% next year. Consensus price target down from US$13.00 to US$11.50. Share price was steady at US$1.12 over the past week.Price Target Changed • Jun 02Price target decreased by 14% to US$11.50Down from US$13.40, the current price target is an average from 4 analysts. New target price is 927% above last closing price of US$1.12. Stock is down 59% over the past year. The company is forecast to post a net loss per share of US$0.90 next year compared to a net loss per share of US$1.42 last year.Major Estimate Revision • May 22Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$26.1m to US$24.0m. Losses expected to increase from US$0.86 per share to US$0.99. Pharmaceuticals industry in the US expected to see average net income decline 17% next year. Consensus price target down from US$13.40 to US$13.00. Share price rose 3.4% to US$1.20 over the past week.Reported Earnings • May 17First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.54 loss per share. Revenue: US$3.17m (up 64% from 1Q 2022). Net loss: US$14.1m (loss widened 5.5% from 1Q 2022). Revenue missed analyst estimates by 49%. Earnings per share (EPS) also missed analyst estimates by 69%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Pharmaceuticals industry in the US.お知らせ • May 09Novan, Inc. to Report Q1, 2023 Results on May 15, 2023Novan, Inc. announced that they will report Q1, 2023 results on May 15, 2023Reported Earnings • Mar 31Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: US$1.42 loss per share. Revenue: US$23.7m (up US$20.7m from FY 2021). Net loss: US$31.3m (loss widened 5.5% from FY 2021). Revenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 6.4%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the US.Price Target Changed • Mar 30Price target decreased by 13% to US$12.67Down from US$14.50, the current price target is an average from 6 analysts. New target price is 956% above last closing price of US$1.20. Stock is down 70% over the past year.Breakeven Date Change • Feb 24Forecast to breakeven in 2025The 6 analysts covering Novan expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$12.4m in 2025. Average annual earnings growth of 60% is required to achieve expected profit on schedule.お知らせ • Jan 07Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum ContagiosumNovan, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum ("molluscum"). Assuming the filing is accepted by the FDA and given a typical 12-month review process, Novan anticipates a potential first quarter 2024 approval. Berdazimer gel, 10.3% is poised to be a first-in-class topical treatment for molluscum. The active ingredient, berdazimer sodium, is a new chemical entity that releases nitric oxide and has anti-viral activity.(4) If approved, berdazimer gel, 10.3% would be the first effective and safe topical treatment indicated for molluscum with the convenience of self-application. Results from the pivotal Phase 3 B-SIMPLE4 clinical study evaluating berdazimer gel, 10.3% for the treatment of molluscum (NCT04535531) demonstrated highly statistically significant improvement in primary clinical endpoint (p< 0.0001) in the largest cohort of molluscum patients ever studied and were recently published in JAMA Dermatology. Berdazimer gel, 10.3% was found to be well tolerated with mild application site pain and mild to moderate erythema reported as the most common adverse events.Seeking Alpha • Aug 10Novan Q2 2022 Earnings PreviewNovan (NASDAQ:NOVN) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.56 (-43.6% Y/Y) and the consensus Revenue Estimate is $6.6M (+791.9% Y/Y). Over the last 1 year, NOVN has beaten EPS estimates 50% of the time and has beaten revenue estimates 25% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 5 upward revisions and 0 downward.Seeking Alpha • Jul 19Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisitionNovan (NASDAQ:NOVN) reached an agreement with Evening Post for payment, satisfaction and termination of its secured promissory note and security agreement related to Mar.11, 2022 acquisition of EPI Health. Novan and EPG agreed that on the latter's receipt of $10M, which Novan subsequently paid, all outstanding indebtedness and obligations of Novan under the promissory note are fully satisfied, and accordingly, the promissory note and related security agreements are terminated. The termination and release will provide $11.1M in savings to shareholders. "We are pleased to announce that the satisfaction of Novan's only outstanding debt, at a substantive 39% discount, and by avoiding $4.6M in future interest payments represents a tremendous opportunity for us," president & CEO Paula Brown Stafford commented. Shares trading 12.7% higher premarket. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、NVN Liquidation は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:NOVN.Q - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202325-32-39-36N/A12/31/202224-31-35-31N/A9/30/202214-37-36-29N/A6/30/20229-37-33-24N/A3/31/20224-34-24-15N/A12/31/20213-30-34-25N/A9/30/20213-28-30-25N/A6/30/20214-30-31-28N/A3/31/20215-32-33-32N/A12/31/20205-29-32-31N/A9/30/20205-29-31-30N/A6/30/20205-30-33-33N/A3/31/20205-30-26-25N/A12/31/20195-30-20-20N/A9/30/20198-17-15-15N/A6/30/20197-15-14-13N/A3/31/20196-14-22-21N/A12/31/20186-13-30-29N/A9/30/20183-28-34-33N/A6/30/20183-28-33-32N/A3/31/20183-30-37-36N/A12/31/20173-37-32-30N/A9/30/20172-42-43-38N/A6/30/20171-52-46-41N/A3/31/20170-60-50-44N/A12/31/2016N/A-60N/A-49N/A9/30/2016N/A-57N/A-41N/A6/30/2016N/A-45N/A-36N/A3/31/2016N/A-32N/A-27N/A12/31/2015N/A-26N/A-22N/A9/30/2015-3-21N/A-17N/A12/31/20140-13N/A-9N/A12/31/20133-6N/A-7N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NOVN.Qの予測収益成長が 貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: NOVN.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: NOVN.Qの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: NOVN.Qの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: NOVN.Qの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NOVN.Qの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/05/01 22:29終値2024/05/01 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NVN Liquidation, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関Brian Kemp DolliverBrookline Capital MarketsJennifer KimCantor Fitzgerald & Co.Donald EllisCitizens JMP Securities, LLC5 その他のアナリストを表示
Price Target Changed • Jul 05Price target decreased by 12% to US$11.50Down from US$13.00, the current price target is an average from 2 analysts. New target price is 2,296% above last closing price of US$0.48. Stock is down 80% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$1.42 last year.
Major Estimate Revision • Jun 02Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$24.0m to US$21.2m. EPS estimate increased from -US$0.994 to -US$0.898 per share. Pharmaceuticals industry in the US expected to see average net income decline 24% next year. Consensus price target down from US$13.00 to US$11.50. Share price was steady at US$1.12 over the past week.
Price Target Changed • Jun 02Price target decreased by 14% to US$11.50Down from US$13.40, the current price target is an average from 4 analysts. New target price is 927% above last closing price of US$1.12. Stock is down 59% over the past year. The company is forecast to post a net loss per share of US$0.90 next year compared to a net loss per share of US$1.42 last year.
Major Estimate Revision • May 22Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$26.1m to US$24.0m. Losses expected to increase from US$0.86 per share to US$0.99. Pharmaceuticals industry in the US expected to see average net income decline 17% next year. Consensus price target down from US$13.40 to US$13.00. Share price rose 3.4% to US$1.20 over the past week.
Price Target Changed • Mar 30Price target decreased by 13% to US$12.67Down from US$14.50, the current price target is an average from 6 analysts. New target price is 956% above last closing price of US$1.20. Stock is down 70% over the past year.
Breakeven Date Change • Feb 24Forecast to breakeven in 2025The 6 analysts covering Novan expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$12.4m in 2025. Average annual earnings growth of 60% is required to achieve expected profit on schedule.
お知らせ • Sep 29Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc.Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) entered into a stalking horse asset purchase agreement to acquire Substantially All of the Assets of Novan, Inc. for $30 million on July 17, 2023. Novan entered into a “stalking horse” asset purchase agreement with Ligand Pharmaceuticals to sell substantially all of the assets of the Company and its subsidiaries, including EPI Health (the “Purchased Assets”) for an upfront payment of $15 million. The cash payable at closing will be reduced dollar-for-dollar by the outstanding balance of the DIP Credit Facility which will be repaid at closing. The Purchase Agreement provides that the Company will pay a break-up fee to Ligand equal to $450,000 upon termination of the transaction in certain circumstances, including the entry into or consummation of an alternative transaction for the Purchased Assets with a party other than Ligand. Ligand Pharmaceuticals provide up to $15 million in DIP financing to Novan inclusive of a $3 million bridge loan already funded. The transaction is part of a sale process under Section 363 of the Bankruptcy Code that will be subject to approval by the Bankruptcy Court and compliance with agreed upon and Bankruptcy Court-approved bidding procedures allowing for the submission of higher or otherwise better offers, and other agreed-upon conditions. The transaction is expected to close in the third quarter of 2023. Gerald F. Roach; Christopher B. Capel; James R. Jolley of Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. and Derek Abbot of Morris, Nichols, Arsht & Tunnell LLP acted as legal advisors for Novan. Craig Wolfe of Morgan, Lewis & Bockius LLP acted as legal advisor for Ligand Pharmaceuticals. Birch Lake is acting as financial advisor for Ligand Pharmaceuticals. Novan engaged Raymond James & Associates, Inc. andSIERRACONSTELLATION PARTNERS LLC. as financial advisor. Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND) completed the acquisition of Substantially All of the Assets of Novan, Inc. on September 27, 2023.
お知らせ • Sep 08Nasdaq To Delist the Common Stock of NovanNasdaq announced that it will delist the common stock of Novan, Inc. Novan, Inc.’s securities were suspended on July 26, 2023, and have not traded on Nasdaq since that time.
お知らせ • Jul 27Novan, Inc.(OTCPK:NOVN.Q) dropped from NASDAQ Composite IndexNovan, Inc. has been dropped from Nasdaq Composite Index.
お知らせ • Jul 18+ 3 more updatesNovan's Securities to Be Delisted from NasdaqAs previously disclosed on July 17, 2023, Novan, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The case will be administered under the caption In re: Novan, Inc. et al, Case No. 23-10937. On July 17, 2023, the Company received written notice (the “Delisting Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, in accordance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1, the staff of Nasdaq has determined that the Company’s securities will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 filing and associated public interest concerns raised by it, concerns regarding the residual equity interest of the existing listed securities holders, and concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. The Company does not intend to appeal the delisting determination. Trading of the Company’s common stock will be suspended at the opening of business on July 26, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the common stock from listing and registration on Nasdaq. As a result, the Company’s common stock is expected to begin trading on the over-the-counter (“OTC”) market on July 26, 2023. On the OTC market, shares of the Company’s common stock, which previously traded on Nasdaq under the symbol NOVN, are expected to trade under the symbol NOVNQ.
お知らせ • Jul 07Novan Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding MVLS RequirementOn June 30, 2023, Novan, Inc. (the Company") received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq") notifying the Company that it is not in compliance with Listing Rule 5550(b)(2), which requires the Company to maintain a minimum market value of listed securities of at least $35 million (the MVLS Requirement") for continued listing on the Nasdaq Capital Market. The letter noted that, as of that date, the Company's market value of listed securities was below $35 million for at least 30 consecutive business days. In accordance with Nasdaq rules, the Company has been provided 180 calendar days, or until December 27, 2023, to regain compliance with the MVLS Requirement or else be subject to delisting. To regain compliance with the MVLS Requirement, the Company's market value of listed securities must close at $35 million or more for a minimum of ten consecutive business days during the 180 calendar-day compliance period. The notification received has no immediate effect on the Company's continued listing on the Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements. The Company continues to manage cash expenditures and cash flows, while pursuing various potential financing and strategic options to, among other things, advance its product candidate for molluscum contagiosum.
Price Target Changed • Jul 05Price target decreased by 12% to US$11.50Down from US$13.00, the current price target is an average from 2 analysts. New target price is 2,296% above last closing price of US$0.48. Stock is down 80% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$1.42 last year.
分析記事 • Jun 07Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)Novan, Inc.'s ( NASDAQ:NOVN ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a buy right now compared...
Major Estimate Revision • Jun 02Consensus revenue estimates decrease by 12%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$24.0m to US$21.2m. EPS estimate increased from -US$0.994 to -US$0.898 per share. Pharmaceuticals industry in the US expected to see average net income decline 24% next year. Consensus price target down from US$13.00 to US$11.50. Share price was steady at US$1.12 over the past week.
Price Target Changed • Jun 02Price target decreased by 14% to US$11.50Down from US$13.40, the current price target is an average from 4 analysts. New target price is 927% above last closing price of US$1.12. Stock is down 59% over the past year. The company is forecast to post a net loss per share of US$0.90 next year compared to a net loss per share of US$1.42 last year.
Major Estimate Revision • May 22Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from US$26.1m to US$24.0m. Losses expected to increase from US$0.86 per share to US$0.99. Pharmaceuticals industry in the US expected to see average net income decline 17% next year. Consensus price target down from US$13.40 to US$13.00. Share price rose 3.4% to US$1.20 over the past week.
Reported Earnings • May 17First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.54 loss per share. Revenue: US$3.17m (up 64% from 1Q 2022). Net loss: US$14.1m (loss widened 5.5% from 1Q 2022). Revenue missed analyst estimates by 49%. Earnings per share (EPS) also missed analyst estimates by 69%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Pharmaceuticals industry in the US.
お知らせ • May 09Novan, Inc. to Report Q1, 2023 Results on May 15, 2023Novan, Inc. announced that they will report Q1, 2023 results on May 15, 2023
Reported Earnings • Mar 31Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: US$1.42 loss per share. Revenue: US$23.7m (up US$20.7m from FY 2021). Net loss: US$31.3m (loss widened 5.5% from FY 2021). Revenue exceeded analyst estimates by 22%. Earnings per share (EPS) also surpassed analyst estimates by 6.4%. Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Pharmaceuticals industry in the US.
Price Target Changed • Mar 30Price target decreased by 13% to US$12.67Down from US$14.50, the current price target is an average from 6 analysts. New target price is 956% above last closing price of US$1.20. Stock is down 70% over the past year.
Breakeven Date Change • Feb 24Forecast to breakeven in 2025The 6 analysts covering Novan expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$12.4m in 2025. Average annual earnings growth of 60% is required to achieve expected profit on schedule.
お知らせ • Jan 07Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (Sb206) for the Treatment of Molluscum ContagiosumNovan, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum ("molluscum"). Assuming the filing is accepted by the FDA and given a typical 12-month review process, Novan anticipates a potential first quarter 2024 approval. Berdazimer gel, 10.3% is poised to be a first-in-class topical treatment for molluscum. The active ingredient, berdazimer sodium, is a new chemical entity that releases nitric oxide and has anti-viral activity.(4) If approved, berdazimer gel, 10.3% would be the first effective and safe topical treatment indicated for molluscum with the convenience of self-application. Results from the pivotal Phase 3 B-SIMPLE4 clinical study evaluating berdazimer gel, 10.3% for the treatment of molluscum (NCT04535531) demonstrated highly statistically significant improvement in primary clinical endpoint (p< 0.0001) in the largest cohort of molluscum patients ever studied and were recently published in JAMA Dermatology. Berdazimer gel, 10.3% was found to be well tolerated with mild application site pain and mild to moderate erythema reported as the most common adverse events.
Seeking Alpha • Aug 10Novan Q2 2022 Earnings PreviewNovan (NASDAQ:NOVN) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.56 (-43.6% Y/Y) and the consensus Revenue Estimate is $6.6M (+791.9% Y/Y). Over the last 1 year, NOVN has beaten EPS estimates 50% of the time and has beaten revenue estimates 25% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 5 upward revisions and 0 downward.
Seeking Alpha • Jul 19Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisitionNovan (NASDAQ:NOVN) reached an agreement with Evening Post for payment, satisfaction and termination of its secured promissory note and security agreement related to Mar.11, 2022 acquisition of EPI Health. Novan and EPG agreed that on the latter's receipt of $10M, which Novan subsequently paid, all outstanding indebtedness and obligations of Novan under the promissory note are fully satisfied, and accordingly, the promissory note and related security agreements are terminated. The termination and release will provide $11.1M in savings to shareholders. "We are pleased to announce that the satisfaction of Novan's only outstanding debt, at a substantive 39% discount, and by avoiding $4.6M in future interest payments represents a tremendous opportunity for us," president & CEO Paula Brown Stafford commented. Shares trading 12.7% higher premarket.